Roger J. M. Brüggemann

Best Publications

• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

  A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning

  1524
  Citations

• Tackling the emerging threat of antifungal resistance to human health

  Unknown

  1283
  Citations

• Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

  Philipp Koehler;Matteo Bassetti;Arunaloke Chakrabarti;Sharon C.A. Chen;Sharon C.A. Chen

  894
  Citations

• Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

  Roger J. M. Bruggemann;Jan-Willem C. Alffenaar;Nicole M. A. Blijlevens;Eliane M. Billaud

  512
  Citations

• Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.

  Paul E. Verweij;Bart J.A. Rijnders;Roger J.M. Brüggemann;Elie Azoulay

  395
  Citations

• International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

  Paul E. Verweij;Michelle Ananda-Rajah;David Andes;Maiken C. Arendrup

  346
  Citations

• European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

  J.A. Maertens;C. Girmenia;R.J.M. Bruggemann;R.F. Duarte

  334
  Citations

• Antifungal drugs: What brings the future?

  Ruth Van Daele;Isabel Spriet;Joost Wauters;Johan Maertens

  216
  Citations

• Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.

  Malgorzata Mikulska;Diana Averbuch;Frederic Tissot;Catherine Cordonnier

  190
  Citations

• Diagnosing COVID-19-associated pulmonary aspergillosis.

  Paul E. Verweij;Jean Pierre Gangneux;Matteo Bassetti;Roger J.M. Brüggemann

  186
  Citations

• Therapeutic drug monitoring of voriconazole.

  Roger J M Brüggemann;J Peter Donnelly;Rob E Aarnoutse;Adilia Warris

  175
  Citations

• Pharmacokinetics and Pharmacodynamics of Posaconazole

  Lu Chen;Elke H. J. Krekels;Paul. E. Verweij;Jochem B. Buil

  159
  Citations

• ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children

  Adilia Warris;Thomas Lehrnbecher;Emmanuel Roilides;Elio Castagnola

  152
  Citations

• Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

  Paul E. Verweij;Paul E. Verweij;Roger J.M. Brüggemann;Elie Azoulay;Matteo Bassetti

  150
  Citations

• Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4

  Andreas H. Groll;Robert Townsend;Amit Desai;Nkechi Azie

  142
  Citations

• Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene

  Eleftheria Mavridou;Roger J. M. Brüggemann;Willem J. G. Melchers;Johan W. Mouton

  140
  Citations

• The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections

  T. Tängdén;V. Ramos Martín;T. W. Felton;E. I. Nielsen

  133
  Citations

• Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1.

  Nico A F Janssen;Rémy Nyga;Lore Vanderbeke;Cato Jacobs

  133
  Citations

• Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

  Eleftheria Mavridou;Roger J. M. Bruggemann;Willem J. G. Melchers;Paul E. Verweij

  120
  Citations

• Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B

  Andreas H Groll;Bart J A Rijnders;Thomas J Walsh;Jill Adler-Moore

  111
  Citations